Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.

Journal: European radiology
PMID:

Abstract

OBJECTIVE: To test the ability of high-performance machine learning (ML) models employing clinical, radiological, and radiomic variables to improve non-invasive prediction of the pathological status of prostate cancer (PCa) in a large, single-institution cohort.

Authors

  • Giulia Marvaso
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Lars Johannes Isaksson
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Mattia Zaffaroni
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mattia.zaffaroni@ieo.it.
  • Maria Giulia Vincini
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. mariagiulia.vincini@ieo.it.
  • Paul Eugene Summers
    Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Matteo Pepa
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Giulia Corrao
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Giovanni Carlo Mazzola
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Marco Rotondi
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Federico Mastroleo
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Sara Raimondi
    Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Sarah Alessi
    Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Paola Pricolo
    Division of Radiology, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Stefano Luzzago
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Francesco Alessandro Mistretta
    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
  • Matteo Ferro
    Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
  • Federica Cattani
    Medical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Francesco Ceci
    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Gennaro Musi
    Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Ottavio De Cobelli
    Department of Urology, European Institute of Oncology (IEO), Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
  • Marta Cremonesi
    Radiation Research Unit, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Sara Gandini
    Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Davide La Torre
    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Roberto Orecchia
    Scientific Directorate, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Giuseppe Petralia
    Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Barbara Alicja Jereczek-Fossa
    Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.